GH Research PLC
NASDAQ:GHRSBiotechnology
-$0.04 today
- Market cap
- $1.25B
- Beta
- 1.31
- P/E (TTM)
- -23.8
- EPS (TTM)
- -$0.91
Volume 0.46M
Average 0.23M
GHRS Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
GH Research PLCNASDAQ: GHRS
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $91K rose 19.7% year over year, ahead of the +12.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 3.4% from the prior quarter. Over 3 fiscal years it compounded at +92.4% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +19.7% holds above the trailing-twelve-month pace of +12.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 335K USD
- Year-over-year change
- +6.3%
- 4-year CAGR
- +104.9%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 335K | +6.3% |
| FY2024 | 2024-12-31 | 315K | +0.0% |
| FY2023 | 2023-12-31 | 315K | +570.2% |
| FY2022 | 2022-12-31 | 47K | +147.4% |
| FY2021 | 2021-12-31 | 19K | — |
Depreciation & Amortization vs competitors
How GHRS compares with its peers on the latest reported figures
- GHRS's LTM Mar 2026 depreciation & amortization of $350K is the 5th largest of the 9 companies compared; the peer median is $449.75K.
- Its year-over-year change of +12.5% is the 3rd highest of 7, against a peer median of -6.4%.
- Over three fiscal years its annual growth of +92.4% compares with a peer median of +92.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $10.32M | +18.9% | +92.7% | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1M | +7.4% | +296.1% | 5.0% |
| LTM Mar 2026 | $674K | +14.4% | +24.6% | — | |
| LTM Mar 2026 | $574K | -20.3% | +0.2% | — | |
| LTM Mar 2026 | $350K | +12.5% | +92.4% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $325.5K | — | +443.4% | — |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $59K | -90.6% | -29.5% | — |
| LTM Jun 2026 | $2.72K | — | +761.4% | — | |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $0 | -100.0% | — | — |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding GHRS) | $449.75K | -6.4% | +92.7% | 5.0% | |
Competitors are the stored peer set for GHRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (9.2M) | (22.46M) | (35.59M) | (38.96M) | (48.26M) |
| Depreciation & Amortization | 19K | 47K | 315K | 315K | 335K |
| Deferred Income Tax | (5.92M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 366K | 1.67M | 2.29M | 1.17M | 0 |
| Change in Working Capital | (559K) | 2.16M | 1.65M | 188K | (3.09M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | (559K) | 2.16M | 1.65M | 188K | (3.09M) |
| Other Non-Cash Items | 9K | (7.62M) | (2M) | (5M) | 7.46M |
| Operating Cash Flow | (15.28M) | (26.2M) | (33.34M) | (42.29M) | (43.55M) |
| Capital Expenditures | (104K) | (67K) | (100K) | (49K) | (121K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (84.62M) | (54M) | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 65.18M | 46.29M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (104K) | (84.69M) | (54.1M) | 65.14M | 46.17M |
| Debt Repayment | 0 | 0 | (219K) | (304K) | 0 |
| Common Stock Issued | 309.2M | 0 | 15K | 0 | 139.85M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (22.75M) | 0 | 0 | 0 | (197K) |
| Financing Cash Flow | 286.45M | 0 | (204K) | (304K) | 139.65M |
| Effect of Forex Changes | (179K) | 66K | 105K | (175K) | 3.19M |
| Net Change in Cash | 270.88M | (110.82M) | (87.54M) | 22.37M | 145.46M |
| Free Cash Flow | (15.39M) | (26.27M) | (33.44M) | (42.33M) | (43.67M) |
GH Research PLC
NASDAQ:GHRS
Intrinsic Alpha fair value
Locked
Current Price
$18.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.